8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2016 / Randomized, double-blind, placebo-controlled trial
In the Madison Memory Study, 218 adults aged 40-91 years with self-reported memory concerns were randomized to receive either an apoaequorin supplement or a matched placebo for 90 days. Cognitive function was evaluated using the computerized CogState International Shopping List (ISL) and ISL-Delayed Recall (ISL-DR) at baseline and multiple points during the study. The apoaequorin group showed statistically significant improvements in verbal learning on the ISL and recall on the ISL-DR over 90 days, and the supplement was well tolerated.
Moran DL, Underwood MY, Gabourie TA, et al. Adv Mind Body Med, 2016. PMID 26878676
2016 / Open-label prospective uncontrolled study
An open-label prospective study prescribed vitamin D at 5000 IU/day during pregnancy to mothers of children with autism, and 1000 IU/day to newborn siblings until their third birthday. Followed for three years and assessed at 18 and 36 months, 1 out of 19 (5%) newborn siblings developed autism, compared to an approximate 20% recurrence rate in the literature. The authors note the study is preliminary, had very small numbers, lacked blinding, and had no control group.
Stubbs G, Henley K, Green J Med Hypotheses, 2016. PMID 26880644
2016 / Interventional study
In subjects with unilateral molar loss, researchers observed asymmetries in pupil size and masticatory muscle electromyographic (EMG) activity during clenching, with the molarless side showing lower EMG activity and a smaller pupil. Treatment with implant-prostheses greatly reduced both the asymmetry in EMG activity and in pupil size. Furthermore, prostheses improved performance in a complex sensorimotor task and increased mydriasis associated with haptic tasks.
De Cicco V, Barresi M, Tramonti Fantozzi MP, et al. PLoS One, 2016. PMID 26919258
2016 / Randomized, double-blind pilot trial
A randomized, double-blind pilot study evaluated the therapeutic role of vitamin B12 in 40 chronic tinnitus patients. Group A (20 patients) received weekly intramuscular vitamin B12 (2500 mcg) for 6 weeks, while Group B (20 patients) received placebo isotonic saline. Vitamin B12 deficiency (<250 pg/ml) was observed in 17 of 40 patients (42.5%). Among patients in Group A with vitamin B12 deficiency, paired t-tests showed significant improvement in mean tinnitus severity index scores and visual analog scale scores after vitamin B12 therapy.
Singh C, Kawatra R, Gupta J, et al. Noise Health, 2016. PMID 26960786
2016 / Randomized controlled trial
Baseline resting BDNF levels were compared between 19 healthy controls and 22 persons with RRMS, after which MS participants were randomized to 24 weeks of exercise (n = 15) or a sedentary control group (n = 7). At baseline, BDNF levels were 21% lower in RRMS participants than in healthy controls. After 24 weeks, BDNF concentrations changed significantly between groups, increasing by 13.9% ± 8.8% in the exercise group and decreasing by 10.5% ± 4.1% in the sedentary group. The exercise group also demonstrated improvements in muscle strength, exercise tolerance, and lean tissue mass, which remained stable in controls.
Wens I, Keytsman C, Deckx N, et al. Eur J Neurol, 2016. PMID 26992038
2016 / 12-month randomized, placebo-controlled, double-blind trial
A 12-month randomized, placebo-controlled, double-blind study evaluated the effect of 1500 mg/d BiocurcumaxTM versus placebo in 96 community-dwelling older adults. A significant time×treatment interaction was detected for the Montreal Cognitive Assessment (F=3.85, P<0.05), driven by a decline in function in the placebo group at 6 months that was not seen in the curcumin group. No differences between the groups were observed for all other clinical and cognitive measures.
Rainey-Smith SR, Brown BM, Sohrabi HR, et al. Br J Nutr, 2016. PMID 27102361
2016 / Double-blind, placebo-controlled, balanced crossover trial
In a balanced crossover trial, 36 adults with type 2 diabetes consumed single doses of synthetic trans-resveratrol (0, 75, 150, and 300 mg) at weekly intervals. CVR to a hypercapnic stimulus was assessed by transcranial Doppler ultrasound before and 45 minutes after treatment. Resveratrol increased CVR in the middle cerebral arteries, with mean within-individual changes from placebo of 13.8 ± 3.5% for 75 mg (P = 0.001), 8.9 ± 3.5% for 150 mg (P = 0.016), and 13.7 ± 3.3% for 300 mg (P < 0.001). Only the 75 mg dose significantly increased CVR in the posterior cerebral arteries (13.2 ± 4.5%, P = 0.016).
Wong RH, Nealon RS, Scholey A, et al. Nutr Metab Cardiovasc Dis, 2016. PMID 27105868
2016 / Multicenter randomized controlled trial
In a multisite trial, 218 healthy nonobese adults were randomized to 2 years of 25% calorie restriction or ad libitum intake. The calorie restriction group lost 7.6 kg versus 0.4 kg in controls (P < 0.001). Compared to controls, calorie restriction improved depressive symptoms, tension, general health, and sexual drive at month 24, as well as sleep duration at month 12 (all P < 0.05), with no adverse quality-of-life effects.
Martin CK, Bhapkar M, Pittas AG, et al. JAMA Intern Med, 2016. PMID 27136347
2016 / Randomized crossover trial
Twenty healthy nonobese men completed an fMRI food picture evaluation task after consuming control inulin or inulin-propionate ester in a randomized crossover design. Increasing colonic propionate reduced the blood oxygen level-dependent signal in the caudate and nucleus accumbens, with the caudate reduction driven specifically by a decreased response to high-energy food. These effects were accompanied by lower subjective appeal of high-energy food pictures and reduced ad libitum energy intake, without changes in plasma PYY, GLP-1, glucose, or insulin.
Byrne CS, Chambers ES, Alhabeeb H, et al. Am J Clin Nutr, 2016. PMID 27169834
2016 / Comparative laboratory and pharmacokinetic study
Researchers analyzed 25 Mucuna pruriens (MP) samples and tested levodopa pharmacokinetics and motor response in four Parkinson's disease patients comparing MP to levodopa plus a dopa-decarboxylase inhibitor (LD+DDCI). Median levodopa concentration was 5.29% in dried seeds and 5.3% in roasted powder, while boiling reduced levodopa content by up to 70%. In patients, MP extract at a similar levodopa dose provided less clinical benefit and yielded a 3.5-fold lower median AUC compared to LD+DDCI. The authors conclude MP may offer clinical benefit only when its levodopa content is at least 3.5-fold higher than standard LD+DDCI formulations.
Cassani E, Cilia R, Laguna J, et al. J Neurol Sci, 2016. PMID 27206902
2016 / Repeated-measures experimental study
A repeated-measures study evaluated affective responses to an 18-hour fasting period compared to a non-fasting period in 52 healthy women (mean age 25). Participants completed diary measures tracking self-reported psychological variables throughout both conditions. Fasting led to increased irritability, alongside positive affective experiences including an increased sense of achievement, reward, pride, and control.
Watkins E, Serpell L Front Nutr, 2016. PMID 27597946
2016 / Randomized, double-blind, controlled clinical trial
Sixty patients with Alzheimer's disease were randomized to receive 200 ml/day of control milk or probiotic milk containing Lactobacillus acidophilus, L. casei, Bifidobacterium bifidum, and L. fermentum for 12 weeks. Compared to controls (-5.03% ± 3.00), the probiotic group showed a significant improvement in MMSE scores (+27.90% ± 8.07, P < 0.001). Probiotic intake also led to significant favorable changes in plasma malondialdehyde, serum hs-CRP, HOMA-IR, beta cell function, serum triglycerides, and QUICKI compared with control (all P < 0.01). No considerable effects were observed on fasting plasma glucose, other lipid profiles, or other biomarkers of oxidative stress and inflammation.
NANO counterpoint →
Akbari E, Asemi Z, Daneshvar Kakhaki R, et al. Front Aging Neurosci, 2016. PMID 27891089
2016 / Randomized crossover trial
In a randomized crossover trial of 27 middle-aged volunteers, participants ingested a 60 ml dose of Montmorency tart cherry concentrate or placebo. Tart cherry intake significantly decreased systolic blood pressure over 3 hours, with peak reductions of 6±2 mmHg at 1 hour compared to placebo. It also altered total and oxygenated hemoglobin levels during cognitive tasks at 1 hour, but cognitive function and mood were not altered.
Keane KM, Haskell-Ramsay CF, Veasey RC, et al. Br J Nutr, 2016. PMID 27989253
2016 / Two randomized controlled trials
Two randomized controlled trials evaluated the effects of flavonoid interventions on serum BDNF and cognitive function. In Trial 1, an 18-week intervention with high-flavonoid fruit and vegetables, but not low-flavonoid, induced significant improvements in cognitive performance and increases in serum BDNF (p < 0.001). In Trial 2, a high-flavanol cocoa drink (494 mg total flavanols) for 12 weeks also significantly increased serum BDNF (p < 0.001), which correlated with improvements in global cognitive performance.
Neshatdoust S, Saunders C, Castle SM, et al. Nutr Healthy Aging, 2016. PMID 28035345
2015 / Randomized controlled trial
A 4-week randomized, double-blind, placebo-controlled trial assessed the effects of gluten and milk on gut permeability and behavior in children with autism spectrum disorders. Intestinal permeability was evaluated using the lactulose:mannitol ratio, alongside standardized behavioral scores and gastrointestinal symptoms. Neither intestinal permeability nor behavioral metrics differed between groups receiving gluten and dairy versus placebo, and observed variations were small and not clinically meaningful.
Navarro F, Pearson DA, Fatheree N, et al. Nutr Neurosci, 2015. PMID 24564346
2015 / Randomized controlled trial (secondary analysis)
In a 6-month trial, 86 women aged 70-80 years with probable mild cognitive impairment were randomly assigned to twice-weekly aerobic training (AT), resistance training (RT), or balance and tone training (BAT, control). Compared with BAT, AT significantly improved left, right, and total hippocampal volumes (p<=0.03). After adjusting for baseline cognitive function and experimental group, increased left hippocampal volume was independently associated with reduced verbal memory and learning performance indexed by loss after interference (r=0.42, p=0.03).
ten Brinke LF, Bolandzadeh N, Nagamatsu LS, et al. Br J Sports Med, 2015. PMID 24711660
2015 / Double-blind, placebo-controlled, randomized clinical trial
A 2-site trial randomized 196 adults with DSM-IV major depressive disorder to 8 weeks of EPA-enriched omega-3 (1,000 mg/d), DHA-enriched omega-3 (1,000 mg/d), or placebo. All three groups exhibited statistically significant improvements in HDRS-17, QIDS-SR-16, and CGI-S scores (P < .05), but neither active preparation separated significantly from placebo (P > .05). Response rates were 40%-50% and remission rates were approximately 30% across all treatments without significant differences between groups.
Mischoulon D, Nierenberg AA, Schettler PJ, et al. J Clin Psychiatry, 2015. PMID 25272149
2015 / Randomized controlled trial
Thirty-one patients with Alzheimer's disease and 31 age-similar controls received a carotenoid formulation (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or sunflower oil placebo for 6 months. Active supplementation significantly raised serum carotenoid concentrations and macular pigment (p < 0.001 for all) and improved contrast sensitivity (p = 0.039). Cognitive function outcomes showed no significant changes in any measured variable (p > 0.05 for all).
Nolan JM, Loskutova E, Howard A, et al. J Alzheimers Dis, 2015. PMID 25408222
2015 / Randomized placebo-controlled trial
In an initial evaluation of 102 young healthy subjects, macular pigment optical density (MPOD) was positively correlated with temporal contrast sensitivity function (tCSF). In a follow-up, 69 subjects were randomized to receive a placebo (n=15) or one of two lutein and zeaxanthin supplements (n=54) for 4 months. Neither MPOD nor tCSF changed in the placebo group, but both improved significantly following supplementation.
Bovier ER, Hammond BR Arch Biochem Biophys, 2015. PMID 25483230
2015 / Randomized double-blind placebo-controlled trial
A four-week randomized, double-blind, placebo-controlled trial tested crocin tablets (30 mg/day) alongside SSRI therapy in 40 patients with major depressive disorder. The crocin group demonstrated significantly greater decreases in Beck Depression Inventory (17.6 vs. 6.15), Beck Anxiety Inventory (12.7 vs. 2.6), and General Health Questionnaire scores (17.2 vs. 10.3) compared to placebo (p < 0.0001). Limitations included a brief intervention period, modest sample size, and dependence on self-reported evaluations.
Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, et al. J Affect Disord, 2015. PMID 25484177
2015 / Randomized clinical trial
Older adults with moderate sleep disturbances were randomized to a 6-week mindful awareness practices (MAPs, n=24) or sleep hygiene education (SHE, n=25) intervention. In intent-to-treat analysis, the MAPs group showed significant improvement on the PSQI compared to the SHE group (between-group mean difference 1.8 [95% CI, 0.6-2.9], effect size 0.89), with postintervention scores of 7.4 (1.9) vs 9.1 (2.0). MAPs also led to significant improvements over SHE in insomnia symptoms, depression symptoms, fatigue interference, and fatigue severity (P < .05 for all), while anxiety, stress, and NF-κB showed no between-group differences.
Black DS, O'Reilly GA, Olmstead R, et al. JAMA Intern Med, 2015. PMID 25686304
2015 / Randomized crossover trial
A randomized crossover trial evaluated 83 migraine patients who followed a low-lipid diet or a normal-lipid diet for 3 months each. Migraine attack frequency dropped significantly more on the low-lipid diet (2.9 +/- 3.7 vs. 6.8 +/- 7.5 attacks, p < 0.001). Attack severity was also lower on the low-lipid diet (1.2 +/- 0.9 vs. 1.7 +/- 0.9, p < 0.01).
Ferrara LA, Pacioni D, Di Fronzo V, et al. Nutr Metab Cardiovasc Dis, 2015. PMID 25698152
2015 / Double-blind cross-over trial
In a double-blind cross-over study, the sleep of 22 young and 24 middle-aged adults was recorded using polysomnography under placebo and caffeine conditions (200 mg and 400 mg). Compared to placebo, caffeine increased sleep latency, shortened total sleep duration, and reduced sleep efficiency, with effects at the 400 mg dose being more pronounced in middle-aged adults. In both age groups, caffeine dose-dependently increased relative stage 1 sleep and reduced absolute and relative slow wave sleep as well as absolute rapid eye movement sleep. The 400 mg dose increased absolute stage 1 sleep in young adults but decreased absolute stage 2 sleep in middle-aged adults.
Robillard R, Bouchard M, Cartier A, et al. J Psychopharmacol, 2015. PMID 25759402
2015 / Randomized, placebo-controlled trial
A 6-month randomized, placebo-controlled trial evaluated 1.5 g of omega-3 fatty acid supplements versus placebo in 38 children aged 2 to 5 years with autism spectrum disorder (ASD). There was no significant difference between groups in the 0- to 24-week change in PDDBI autism composite scores (p = 0.5), adaptive function (p = 0.09), or language gains (p = 0.6). A significant group by week interaction was observed for the BASC-2 externalizing problem score, with participants in the omega-3 group showing worsening scores (p = 0.02). Omega-3s were relatively well tolerated, and changes in cytokine profiles did not significantly correlate with treatment response.
Mankad D, Dupuis A, Smile S, et al. Mol Autism, 2015. PMID 25798215